vs
Side-by-side financial comparison of Crexendo, Inc. (CXDO) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $18.1M, roughly 1.6× Crexendo, Inc.). Crexendo, Inc. runs the higher net margin — 6.7% vs -147.1%, a 153.9% gap on every dollar of revenue. On growth, Crexendo, Inc. posted the faster year-over-year revenue change (11.2% vs -67.6%).
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CXDO vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.1M | $28.1M |
| Net Profit | $1.2M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 6.3% | -147.6% |
| Net Margin | 6.7% | -147.1% |
| Revenue YoY | 11.2% | -67.6% |
| Net Profit YoY | 140.2% | -182.8% |
| EPS (diluted) | $0.03 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.1M | $28.1M | ||
| Q3 25 | $17.5M | $32.5M | ||
| Q2 25 | $16.6M | $15.7M | ||
| Q1 25 | $16.1M | $8.0M | ||
| Q4 24 | $16.2M | $86.6M | ||
| Q3 24 | $15.6M | $2.1M | ||
| Q2 24 | $14.7M | $500.0K | ||
| Q1 24 | $14.3M | $0 |
| Q4 25 | $1.2M | $-41.3M | ||
| Q3 25 | $1.4M | $-51.2M | ||
| Q2 25 | $1.2M | $-44.9M | ||
| Q1 25 | $1.2M | $-33.9M | ||
| Q4 24 | $507.0K | $49.9M | ||
| Q3 24 | $148.0K | $-19.1M | ||
| Q2 24 | $588.0K | $-12.5M | ||
| Q1 24 | $434.0K | $-10.3M |
| Q4 25 | 6.3% | -147.6% | ||
| Q3 25 | 7.5% | -163.7% | ||
| Q2 25 | 6.7% | -302.9% | ||
| Q1 25 | 7.2% | -466.3% | ||
| Q4 24 | 3.9% | 54.5% | ||
| Q3 24 | 0.9% | -1051.6% | ||
| Q2 24 | 3.9% | -3068.0% | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 6.7% | -147.1% | ||
| Q3 25 | 8.3% | -157.4% | ||
| Q2 25 | 7.4% | -285.6% | ||
| Q1 25 | 7.3% | -425.7% | ||
| Q4 24 | 3.1% | 57.7% | ||
| Q3 24 | 0.9% | -925.0% | ||
| Q2 24 | 4.0% | -2503.2% | ||
| Q1 24 | 3.0% | — |
| Q4 25 | $0.03 | $-0.41 | ||
| Q3 25 | $0.05 | $-0.52 | ||
| Q2 25 | $0.04 | $-0.46 | ||
| Q1 25 | $0.04 | $-0.35 | ||
| Q4 24 | $0.03 | $0.52 | ||
| Q3 24 | $0.00 | $-0.20 | ||
| Q2 24 | $0.02 | $-0.13 | ||
| Q1 24 | $0.01 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | $114.0K | $96.4M |
| Stockholders' EquityBook value | $63.8M | $114.3M |
| Total Assets | $77.7M | $327.7M |
| Debt / EquityLower = less leverage | 0.00× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
| Q4 25 | $114.0K | $96.4M | ||
| Q3 25 | $236.0K | $96.2M | ||
| Q2 25 | $356.0K | — | ||
| Q1 25 | $475.0K | — | ||
| Q4 24 | $592.0K | $0 | ||
| Q3 24 | $709.0K | — | ||
| Q2 24 | $823.0K | — | ||
| Q1 24 | $937.0K | — |
| Q4 25 | $63.8M | $114.3M | ||
| Q3 25 | $61.3M | $147.7M | ||
| Q2 25 | $58.3M | $192.3M | ||
| Q1 25 | $55.2M | $229.0M | ||
| Q4 24 | $51.4M | $256.8M | ||
| Q3 24 | $49.5M | $201.0M | ||
| Q2 24 | $48.2M | $215.2M | ||
| Q1 24 | $46.8M | $223.9M |
| Q4 25 | $77.7M | $327.7M | ||
| Q3 25 | $76.0M | $372.8M | ||
| Q2 25 | $71.4M | $313.5M | ||
| Q1 25 | $67.4M | $327.3M | ||
| Q4 24 | $64.9M | $351.2M | ||
| Q3 24 | $62.3M | $217.6M | ||
| Q2 24 | $59.6M | $222.0M | ||
| Q1 24 | $57.5M | $227.6M |
| Q4 25 | 0.00× | 0.84× | ||
| Q3 25 | 0.00× | 0.65× | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | 0.00× | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.93× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $-43.5M | ||
| Q3 25 | $4.4M | $-47.0M | ||
| Q2 25 | $1.3M | $-39.6M | ||
| Q1 25 | $1.2M | $-40.7M | ||
| Q4 24 | $2.2M | $42.0M | ||
| Q3 24 | $1.6M | $-14.5M | ||
| Q2 24 | $2.7M | $-7.3M | ||
| Q1 24 | $-166.0K | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | $1.3M | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | $2.1M | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | 7.7% | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | 13.2% | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 0.0% | 1.1% | ||
| Q4 24 | 0.2% | 0.3% | ||
| Q3 24 | 0.0% | 6.8% | ||
| Q2 24 | 0.0% | 7.6% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.29× | 0.84× | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
